Cyclic Peptide Drugs Are Coming of Age — From Lab Curiosity to FDA Approval
Cyclic peptides — ring-shaped drug molecules that can potentially be taken as pills — are reaching the market through new screening technologies, marking a maturation of the field.
Quick Facts
What This Study Found
Cyclic peptide drug discovery has reached a turning point. For decades, cyclic peptide drugs came almost exclusively from natural products (compounds found in nature). But in recent years, display screening technologies — particularly phage display and mRNA display — have matured enough that the first de novo (designed-from-scratch) cyclic peptide drugs discovered through these methods have reached the market.
Cyclic peptides occupy a unique therapeutic sweet spot: they can hit a broader range of protein targets than traditional small-molecule drugs, while also being potentially capable of oral availability and cell penetration — two properties that most peptide drugs lack. However, significant technical challenges remain, particularly in engineering membrane permeability and oral bioavailability for intracellular targets.
Key Numbers
Two decades of display technology development · First de novo display-derived cyclic peptides reaching market · Many more in clinical trials · Broader target range than small molecules
How They Did This
Expert review article surveying the clinical landscape for cyclic peptide drugs, comparing natural product-derived versus display-derived discovery approaches, and assessing the technical challenges remaining in the field.
Why This Research Matters
Most peptide drugs require injection, which limits their use. Cyclic peptides — peptides bent into a ring shape — have the rare potential to be taken as pills and to enter cells. This review documents a major milestone: the field has moved from purely academic to producing FDA-approved drugs from display screening, marking cyclic peptides as one of the most promising frontiers in pharmaceutical development.
The Bigger Picture
Cyclic peptides represent one of the most exciting frontiers in drug development because they bridge the gap between small-molecule drugs (easy to take as pills but limited targets) and biologic drugs (powerful but require injection). This review documents the field's transition from academic research to commercial reality, with implications for treating diseases that currently have no good drug targets.
What This Study Doesn't Tell Us
As a review, no new experimental data is presented. The assessment of the field's maturity and remaining challenges reflects the authors' expert perspective. Specific clinical pipeline data may have changed since publication.
Questions This Raises
- ?Which specific intracellular protein targets are most likely to be addressed by the next generation of cyclic peptide drugs?
- ?How will AI-driven design complement display screening in accelerating cyclic peptide discovery?
- ?Can the oral bioavailability challenge be solved generally, or will each cyclic peptide need individual optimization?
Trust & Context
- Key Stat:
- First de novo cyclic peptides reach market After two decades of developing display screening technologies, the first cyclic peptide drugs designed from scratch (not from nature) have been approved
- Evidence Grade:
- This is an expert review in a specialized drug discovery journal that surveys the clinical landscape and technology developments. It synthesizes evidence across the field without presenting new experimental data.
- Study Age:
- Published in 2024, this is a very current review that captures the field at a pivotal moment — when de novo cyclic peptide drugs are first reaching the market. The landscape described is likely still accurate.
- Original Title:
- The coming of age of cyclic peptide drugs: an update on discovery technologies.
- Published In:
- Expert opinion on drug discovery, 19(8), 961-973 (2024)
- Authors:
- You, Sophia, McIntyre, Glen, Passioura, Toby(2)
- Database ID:
- RPEP-09609
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What makes cyclic peptides different from regular peptides?
Regular (linear) peptides are chain-shaped and usually break down quickly in the stomach and can't cross cell membranes. Cyclic peptides are bent into a ring shape, which makes them more stable, potentially absorbable as pills, and capable of entering cells — properties that most peptide drugs lack.
What are display screening technologies and why do they matter?
Display screening (like phage display and mRNA display) lets scientists test billions or trillions of cyclic peptide candidates at once to find ones that bind a specific disease target. Before these technologies, cyclic peptide drugs could only be found in nature. Now scientists can design them from scratch, dramatically expanding the range of diseases that cyclic peptides can treat.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09609APA
You, Sophia; McIntyre, Glen; Passioura, Toby. (2024). The coming of age of cyclic peptide drugs: an update on discovery technologies.. Expert opinion on drug discovery, 19(8), 961-973. https://doi.org/10.1080/17460441.2024.2367024
MLA
You, Sophia, et al. "The coming of age of cyclic peptide drugs: an update on discovery technologies.." Expert opinion on drug discovery, 2024. https://doi.org/10.1080/17460441.2024.2367024
RethinkPeptides
RethinkPeptides Research Database. "The coming of age of cyclic peptide drugs: an update on disc..." RPEP-09609. Retrieved from https://rethinkpeptides.com/research/you-2024-the-coming-of-age
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.